The Motley Fool
02 Aug 2026, 11:55 UTC · 2h ago
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
02 Aug 2026, 11:55 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Eli Lilly reported a massive 44.7% year-over-year revenue increase in FY 2025, reaching approximately $65.2 billion. — Extreme top-line growth driven by high-demand obesity and diabetes drugs is a primary driver for valuation and risk appetite in the biotech sector.
+0.80Eli Lilly exhibits high customer concentration risk, relying heavily on three major wholesalers: McKesson, Cencora, and Cardinal Health. — Heavy reliance on a small number of distributors creates a structural vulnerability that could negatively affect the stock if partnership terms change.
-0.40Abbott Laboratories grew revenue by 5.7% to nearly $44.3 billion in FY 2025 with a net income of roughly $6.5 billion. — Steady, moderate growth and consistent profitability reinforce a low-risk, defensive investment profile.
+0.30Continue reading
6 related stories
Search tags
Abbott Laboratories maintains a conservative financial structure with a debt-to-equity ratio of approximately 0.3x and a current ratio of 1.6x. — Strong balance sheet metrics reduce solvency risk and provide stability during market volatility.
+0.20Which stocks this story touches
Highlighted as a powerhouse with massive revenue surges driven by breakthrough obesity and diabetes treatments.
Described as a diversified healthcare giant with steady growth, strong free cash flow, and a conservative financial structure.
Mentioned only as a wholesaler that Eli Lilly depends on, without specific positive or negative news for Cardinal Health itself.
Mentioned only as a wholesaler that Eli Lilly depends on, without specific positive or negative news for Cencora itself.
Mentioned only as a wholesaler that Eli Lilly depends on, without specific positive or negative news for McKesson itself.
[a_to_b] Cardinal Health is one of three major wholesalers that Eli Lilly depends heavily on for distribution.
[a_to_b] Cencora is one of three major wholesalers that Eli Lilly depends heavily on for distribution.
[a_to_b] McKesson is one of three major wholesalers that Eli Lilly depends heavily on for distribution.
[mutual] The article compares the two as healthcare investment options, though they operate in different primary segments (diversified medical devices vs. pharmaceutical growth).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
24/7 Wall Street
3h ago
